Prolyl-4-hydroxylase PHD2- and hypoxia-inducible factor 2-dependent regulation of amphiregulin contributes to breast tumorigenesis

Oncogene

Volumn 30, Issue 5, 2011, Pages 548-560

  Bordoli, M R ^a   Stiehl, D P ^a   Borsig, L ^a   Kristiansen, G ^b   Hausladen, S ^b   Schraml, P ^b   Wenger, R H ^a   Camenisch, G ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

amphiregulin; hypoxia inducible factors; mammary carcinoma; prolyl 4 hydroxylases; tumor vascularization

Indexed keywords

AMPHIREGULIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL TIME; TISSUE MICROARRAY; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, NUDE; MIDDLE AGED; PROCOLLAGEN-PROLINE DIOXYGENASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 79551629623     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.433     Document Type: Article

References (52)

1. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH et al. (2001). Expression of hypoxia-inducible factor-1a: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61: 2911-2916.
2. Balamurugan K, Luu VD, Kaufmann MR, Hofmann VS, Boysen G, Barth S et al. (2009). Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response. Oncogene 28: 3274-3285.
3. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW et al. (1994). Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem 269: 22817-22822.
4. Barth S, Nesper J, Hasgall PA, Wirthner R, Nytko KJ, Edlich F et al. (2007). The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol Cell Biol 27: 3758-3768.
5. Brown JM, Wilson WR. (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437-447.
6. Bruick RK, McKnight SL. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337-1340.
7. Camenisch G, Tini M, Chilov D, Kvietikova I, Srinivas V, Caro J et al. (1999). General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1a. FASEB J 13: 81-88.
8. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. (2009). Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538.
9. Chokki M, Mitsuhashi H, Kamimura T. (2006). Metalloprotease-dependent amphiregulin release mediates tumor necrosis factor-alpha-induced IL-8 secretion in the human airway epithelial cell line NCI-H292. Life Sci 78: 3051-3057.
10. Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F et al. (2008). Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res 14: 6634-6639.
11. Elston EW, Ellis IO. (1993). Method for grading breast cancer. J Clin Pathol 46: 189-190.
12. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR et al. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54.
13. Erez N, Milyavsky M, Eilam R, Shats I, Goldfinger N, Rotter V. (2003). Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1a activation and inhibits tumor growth. Cancer Res 63: 8777-8783.
14. Franovic A, Holterman CE, Payette J, Lee S. (2009). Human cancers converge at the HIF-2a oncogenic axis. Proc Natl Acad Sci USA 106: 21306-21311.
15. Giusti C, Desruisseau S, Ma L, Calvo F, Martin PM, Berthois Y. (2003). Transforming growth factor beta-1 and amphiregulin act in synergy to increase the production of urokinase-type plasminogen activator in transformed breast epithelial cells. Int J Cancer 105: 769-778.
16. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Gunzler V, Kondo K et al. (2002). Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA 99: 13459-13464.
17. 2-regulated prolyl hydroxylation. Science 292: 468-472.
18. Jokilehto T, Rantanen K, Luukkaa M, Heikkinen P, Grenman R, Minn H et al. (2006). Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness. Clin Cancer Res 12: 1080-1087.
19. Kato H, Inoue T, Asanoma K, Nishimura C, Matsuda T, Wake N. (2006). Induction of human endometrial cancer cell senescence through modulation of HIF-1a activity by EGLN1. Int J Cancer 118: 1144-1153.
20. Lamber EP, Horwitz AA, Parvin JD. (2010). BRCA1 represses amphiregulin gene expression. Cancer Res 70: 996-1005.
21. Le Bras A, Lionneton F, Mattot V, Lelievre E, Caetano B, Spruyt N et al. (2007). HIF-2a specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26: 7480-7489.
22. Lee KA, Lynd JD, O'Reilly S, Kiupel M, McCormick JJ, LaPres JJ. (2008). The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 6: 829-842.
23. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP et al. (2005). Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167.
24. Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA et al. (1999). The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell 98: 663-673.
25. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A et al. (1999). Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 126: 2739-2750.
26. Ma L, Gauville C, Berthois Y, Millot G, Johnson GR, Calvo F. (1999). Antisense expression for amphiregulin suppresses tumor-igenicity of a transformed human breast epithelial cell line. Oncogene 18: 6513-6520.
27. Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normanno N, Salomon DS et al. (1995). Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology 136: 3983-3992.
28. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275.
29. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B et al. (2009). Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136: 839-851.
30. McBryan J, Howlin J, Napoletano S, Martin F. (2008). Amphiregulin: role in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 13: 159-169.
31. Metzen E, Stiehl DP, Doege K, Marxsen JH, Hellwig-Burgel T, Jelkmann W. (2005). Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochem J 387: 711-717.
32. O'Reilly SM, Leonard MO, Kieran N, Comerford KM, Cummins E, Pouliot M et al. (2006). Hypoxia induces epithelial amphiregulin gene expression in a CREB-dependent manner. Am J Physiol Cell Physiol 290: C592-C600.
33. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M et al. (1996). Differential immunohistochemical detection of transforming growth factor a, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 65: 51-56.
34. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ et al. (1990). The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 10: 1969-1981.
35. Pouyssegur J, Dayan F, Mazure NM. (2006). Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
36. Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ et al. (1994). Expression of transforming growth factor a, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 69: 903-910.
37. Semenza GL. (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
38. Shoyab M, McDonald VL, Bradley JG, Todaro GJ. (1988). Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85: 6528-6532.
39. Stiehl DP, Wirthner R, Koditz J, Spielmann P, Camenisch G, Wenger RH. (2006). Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an auto-regulatory oxygen-sensing system. J Biol Chem 281: 23482-23491.
40. Takeda K, Cowan A, Fong GH. (2007). Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116: 774-781.
41. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B et al. (2007). NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. Int J Cancer 120: 2411-2417.
42. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA et al. (2004). Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36: 782-801.
43. Wanner RM, Spielmann P, Stroka DM, Camenisch G, Camenisch I, Scheid A et al. (2000). Epolones induce erythropoietin expression via hypoxia-inducible factor-1a activation. Blood 96: 1558-1565.
44. Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S et al. (2003). Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17: 1186-1188.
45. 2-regulated gene expression. FASEB J 16: 1151-1162.
46. Wenger RH, Stiehl DP, Camenisch G. (2005). Integration of oxygen signaling at the consensus HRE. Sci STKE 306: re12.
47. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL et al. (1998). Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1a. Blood 92: 2260-2268.
48. Willmarth NE, Ethier SP. (2008). Amphiregulin as a novel target for breast cancer therapy. J Mammary Gland Biol Neoplasia 13: 171-179.
49. Wu S, Nishiyama N, Kano MR, Morishita Y, Miyazono K, Itaka K et al. (2008). Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene. Mol Ther 16: 1227-1234.
50. Xue J, Li X, Jiao S, Wei Y, Wu G, Fang J. (2010). Prolyl hydroxylase-3 is downregulated in colorectal cancer cells and inhibits IkKb, independent of hydroxylase activity. Gastroenterology 138: 606-615.
51. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW et al. (2009). Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell 16: 413-424.
52. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al. (1999). Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res 59: 5830-5835.